<DOC>
	<DOCNO>NCT00812058</DOCNO>
	<brief_summary>The purpose study test new drug , RG2417 , see drug affect symptoms bipolar I depression make sure safe human .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Efficacy RG2417 Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<criteria>Bipolar I Disorder , recent episode depress History 2 manic mixed episode , least one require pharmacologic treatment manic symptom Current manic , hypomanic mixed episode Rapid cycling bipolar disorder ( 4 mood episode last year ) Dementia Axis I diagnosis ( besides bipolar I ) require treatment Alcohol drug dependence within 6 month ; alcohol drug abuse within 3 month Positive urine drug test amphetamine , cocaine metabolite , opiates and/or phencyclidine ( PCP ) Axis II diagnosis likely interfere study compliance Serious suicidal homicidal risk Sensitivity drug ingredient , include lactose Women pregnant , breast feeding refuse use adequate birth control Current seizure disorder Current episode depression longer 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bipolar Depression</keyword>
	<keyword>Bipolar Disease</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar</keyword>
	<keyword>Manic Depression</keyword>
	<keyword>Manic Depressive Disorder</keyword>
</DOC>